Skip to content

Study · Animal study (in vivo) · mouse · 2015

5 results

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease.

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Moessler H, Masliah E

Journal of experimental neuroscience1 Jan 2015Cited by 6 (Europe PMC)

PMID27429559 (opens in a new tab)PMCIDPMC4938121 (opens in a new tab)DOI10.4137/jen.s25521 (opens in a new tab)PepBankPUB-27429559
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In α-synuclein transgenic mice with neural stem cell grafts, Cerebrolysin enhanced NSC survival compared with vehicle treatment.

    In plain wordsIn α-synuclein transgenic mice, Cerebrolysin increased grafted neural stem cell survival compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGrafted NSC survival
    Study

    mousen: not reported in source

    Neural stem cell grafts in α-synuclein transgenic mice
    Comparator
    Vehicle-treated α-syn transgenic mice with neural stem cell grafts
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, CBL treatment enhanced the survival of NSCs in α-syn tg groups and ameliorated behavioral deficits.
    2 context sentences
    Summary · context
    In vehicle-treated α-syn tg mice, there was decreased survival of NSCs.
    Summary · context
    We investigated the use of Cerebrolysin (CBL), a neurotrophic peptide mixture, as an adjunct to NSC therapy in the α-synuclein (α-syn) transgenic (tg) model of PD.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In α-synuclein transgenic mice with neural stem cell grafts, Cerebrolysin ameliorated behavioral deficits compared with vehicle treatment.

    In plain wordsIn α-synuclein transgenic mice, Cerebrolysin reduced behavioral deficits compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseBehavioral deficits
    Study

    mousen: not reported in source

    Neural stem cell grafts in α-synuclein transgenic mice
    Comparator
    Vehicle-treated α-syn transgenic mice with neural stem cell grafts
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, CBL treatment enhanced the survival of NSCs in α-syn tg groups and ameliorated behavioral deficits.
    2 context sentences
    Summary · context
    In vehicle-treated α-syn tg mice, there was decreased survival of NSCs.
    Summary · context
    We investigated the use of Cerebrolysin (CBL), a neurotrophic peptide mixture, as an adjunct to NSC therapy in the α-synuclein (α-syn) transgenic (tg) model of PD.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In α-synuclein transgenic mice, grafted NSCs showed fewer TUNEL positive cells with Cerebrolysin than with vehicle treatment.

    In plain wordsIn α-synuclein transgenic mice, Cerebrolysin reduced TUNEL positive grafted neural stem cells compared with vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseTUNEL positive grafted cells
    Study

    mousen: not reported in source

    Neural stem cell grafts in α-synuclein transgenic mice
    Comparator
    Vehicle-treated α-syn transgenic mice with neural stem cell grafts
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The grafted NSCs showed lower levels of terminal deoxynucleotidyl transferase dUTP nick end labeling positive cells in the CBL-treated mice when compared with vehicle-treated α-syn tg mice.
    1 context sentence
    Summary · context
    We investigated the use of Cerebrolysin (CBL), a neurotrophic peptide mixture, as an adjunct to NSC therapy in the α-synuclein (α-syn) transgenic (tg) model of PD.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In the neural stem cell graft study involving Cerebrolysin-treated mice, no evidence of tumor growth was detected.

    In plain wordsIn mice in the neural stem cell graft study involving Cerebrolysin, no evidence of tumor growth was detected.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableTumor growth
    Study

    mousen: not reported in source

    Neural stem cell grafts in α-synuclein transgenic mice
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No evidence of tumor growth was detected.
    1 context sentence
    Summary · context
    We investigated the use of Cerebrolysin (CBL), a neurotrophic peptide mixture, as an adjunct to NSC therapy in the α-synuclein (α-syn) transgenic (tg) model of PD.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In transgenic mice with neural stem cell grafts, α-synuclein levels were similar with Cerebrolysin and vehicle treatment.

    In plain wordsIn transgenic mice, α-synuclein levels were similar with Cerebrolysin and vehicle treatment.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeα-synuclein levels
    Study

    mousen: not reported in source

    Neural stem cell grafts in α-synuclein transgenic mice
    Comparator
    Vehicle-treated α-syn transgenic mice with neural stem cell grafts
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Levels of α-syn were similar in the vehicle in CBL-treated tg mice.
    1 context sentence
    Summary · context
    We investigated the use of Cerebrolysin (CBL), a neurotrophic peptide mixture, as an adjunct to NSC therapy in the α-synuclein (α-syn) transgenic (tg) model of PD.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.